ArticleFrontiers in immunology2025
Impact of vaccination strategy adjustments on antibody levels against measles, rubella, mumps, and varicella in China: a single-center serological survey.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Waning Measles Immunity and Sustained Rubella Seroprotection Among Adults in Istanbul, Türkiye.Medicina (Kaunas, Lithuania) · 2026Article
- Varicella vaccination in children with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluated trends in population immunity against measles, rubella, mumps, and varicella in Suqian City (2005-2024) using serological surveys (2019-2024) and incidence data, incorporating participants with known/unknown vaccination statuses to explore immunity dynamics amid evolving policies, and inform public health planning. Methods: Serum samples from 541 (2019) and 506 (2024) healthy participants were analyzed for virus-specific IgG antibodies using ELISA. Disease incidence data were obtained from China's National Notifiable Disease Reporting System. Statistical analyses compared seroprevalence, geometric mean concentrations (GMCs), and incidence trends before and after policy adjustments. Results: Optimized two-dose strategies significantly improved seropositivity rates for rubella (65.1% to 70.8%), mumps (77.6% to 85.8%), and varicella (76.9% to 79.5%), with corresponding GMC increases. Incidence declines were notable: varicella (183.3/100,000 to 59.3/100,000), rubella (2.8/100,000 to 0.04/100,000), and mumps (24.4/100,000 to <5.0/100,000). However, measles seropositivity declined from 85.9% to 79.3% (p<0.05). GMC analysis showed increases for rubella (31.5 to 42.2 IU/ml), mumps (277.8 to 350.6 IU/ml), and varicella (295.9 to 309.8 IU/ml), but a decrease for measles (577.9 to 499.2 mIU/ml, p<0.001). Preschool children (2-5 years) exhibited the highest immunity levels in 2024. Conclusion: Population immunity against rubella, mumps, and varicella improved (2019-2024) with reduced incidence, while measles immunity declined, revealing vulnerabilities. Targeted strategies (e.g., catch-up campaigns for adolescents/adults, optimized infant vaccination) are needed to strengthen protection, considering interactions of policies, public health measures, and demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.